Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Agios Pharmaceuticals, Inc.
13G/A
Amendment 12
AGIO · 00847X104
|
0% |
6/13/2025
Event 6/1/2025
|
|||
| BB Biotech AG | 0% | ||||
| Biotech Target N.V. | 0% | ||||
|
Macrogenics Inc
13G/A
Amendment 11
MGNX · 556099109
|
0% |
6/13/2025
Event 6/1/2025
|
|||
| BB Biotech AG | 0% | ||||
| Biotech Target N.V. | 0% | ||||
|
Black Diamond Therapeutics, Inc.
13G/A
Amendment 6
BDTX · 09203E105
|
4.8% |
3/21/2025
Event 3/19/2025
|
|||
| BB Biotech AG | 4.8% | ||||
| Biotech Growth N.V. | 4.8% | ||||
|
Esperion Therapeutics, Inc.
13G/A
Amendment 13
ESPR · 29664W105
|
4.9% |
3/10/2025
Event 3/4/2025
|
|||
| BB Biotech AG | 4.9% | ||||
| Biotech Target N.V. | 4.9% | ||||
|
MacroGenics Inc
13G/A
Amendment 10
MGNX · 556099109
|
15.8% |
2/14/2025
Event 12/31/2024
|
|||
| BB Biotech AG | 15.8% | ||||
| Biotech Target N.V. | 15.8% | ||||
|
Esperion Therapeutics, Inc.
13G/A
Amendment 12
ESPR · 29664W105
|
5.0% |
2/14/2025
Event 12/31/2024
|
|||
| BB Biotech AG | 5.0% | ||||
| Biotech Target N.V. | 5.0% | ||||
|
Black Diamond Therapeutics, Inc.
13G/A
Amendment 5
BDTX · 09203E105
|
15.1% |
2/14/2025
Event 12/31/2024
|
|||
| BB Biotech AG | 15.1% | ||||
| Biotech Growth N.V. | 15.1% | ||||
|
Agios Pharmaceuticals, Inc.
13G/A
Amendment 11
AGIO · 00847X104
|
6.2% |
2/14/2025
Event 12/31/2024
|
|||
| BB Biotech AG | 6.2% | ||||
| Biotech Target N.V. | 6.2% | ||||
|
Sage Therapeutics, Inc.
13G/A
Amendment 3
SAGE · 78667J108
|
1.9% |
1/17/2025
Event 1/13/2025
|
|||
| BB Biotech AG | 1.9% | ||||
| Biotech Target N.V. | 1.9% | ||||